Laimei Pharmaceutical (300006.SZ): Application for marketing of the chemical ingredient teribapressin acetate approved

Zhitong Finance ·  12/30/2022 18:36

According to the Zhitong Finance App, Laimei Pharmaceutical (300006.SZ) issued an announcement. Recently, Chongqing Laimei Longyu Pharmaceutical Co., Ltd. (“Laimei Longyu”), a wholly-owned subsidiary of the company, received the approval and issuance of the “Chemical Ingredient Drug Marketing Application Approval Notice” (acceptance number: CYHS2060492) for telibapressin acetate with a specification of 30g/piece from the China Drug Administration.

According to reports, the raw material of teripressin acetate is used in the production of injectable teribapressin preparations. Teripressin is a synthetic vasopressin analog. It is a vasoconstrictor drug among vasoactive drugs. It is mainly used to stop bleeding from cirrhosis, varicose veins, and bleeding. Currently, it is widely used clinically in the treatment of hepatorenal syndrome, cirrhosis, ascites, infectious shock, burns, acute liver failure, cardiac arrest, etc.

This page is machine-translated. Futubull tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

    Write first comment